Precision Therapy in NSCLC: Pharmacist Perspectives on Testing Strategies and Biomarker-Driven Treatment Approaches

Activity Details
  • Credit Amounts:
    • CPE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Apr 13, 2020
  • Expires: Apr 13, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Target Audience

This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.

Objectives

1. Review the most recent molecular testing guidelines for non-small cell lung cancer (NSCLC), including clinically relevant biomarkers, recommended testing modalities, and implications for currently available and evolving treatments.

2. Examine targeted therapies currently approved for NSCLC and appraise biomarker-driven approaches to selection and sequencing of therapy.

3. Using a case-based approach, evaluate adaptive strategies pharmacists can employ to expand the uptake of guideline-recommended biomarker testing and ensure the appropriate selection of targeted therapy based on patient- and biomarker-specific factors.

Accreditation

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.0 contact hour (0.01 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-011-H01-P).

Acknowledgment

Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.